On October 8, 2019 Veracyte, Inc. (Nasdaq: VCYT) reported that it will release its financial results for the third quarter 2019 and business progress after the close of market on Tuesday, October 22, 2019 (Press release, Veracyte, OCT 8, 2019, View Source [SID1234540118]). Company management will host a conference call and webcast to discuss its financial results and provide a general business update at 5:00 p.m. Eastern time on the same day.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference call will be webcast live from the company’s website and will be available via the following link: View Source The webcast should be accessed 10 minutes prior to the conference call start time. A replay of the webcast will be available for one year following the conclusion of the live broadcast and will be accessible on the company’s website at View Source

The conference call can be accessed as follows:

U.S./Canada participant dial-in number (toll-free):

(855) 541-0980

International participant dial-in number:

(970) 315-0440

Conference I.D.:

8767084

On October 8, 2019 Illumina, Inc. (NASDAQ:ILMN) reported that it will issue results for third quarter 2019 following the close of market on Thursday, October 24, 2019 (Press release, Illumina, OCT 8, 2019, View Source [SID1234540116]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Francis deSouza, President and Chief Executive Officer, and Sam Samad, Senior Vice President and Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.

Conference Call Details

The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Thursday, October 24, 2019. Interested parties may access the live teleconference through the Investor Relations section of Illumina’s website under the "company" tab at www.illumina.com. Alternatively, individuals can access the call by dialing 1 (866) 211-4597 or 1 (647) 689-6853 outside North America, both with conference ID 2388693.

A replay of the conference call will be posted on Illumina’s website after the event and will be available for at least 30 days following.

On October 8, 2019 Median Technologies (Paris:ALMDT), The Imaging Phenomics Company, reported an update on its performance unaudited figures – in the third quarter of 2019 (Press release, MEDIAN Technologies, OCT 8, 2019, View Source [SID1234540115]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As of September 30th, 2019, the cumulated revenue for 2019 was € 6.3 million. In the first three quarters of 2019, the company has already generated equivalent revenues to the full 2018 year (€ 6.3 million). Sales in the third quarter 2019 grew to € 2.3 million, making it the fourth quarter in a row that the company experienced steady growth. Median’s revenue came solely from its iCRO1 business.

As of September 30th, 2019, the order backlog reached € 35.9 million, an increase of € 5.2 million since June 30th, 2019 and an increase of € 12.2 million compared to December 31st, 2018.

Considering the company’s positive performance and the Research Tax Credit payment (€ 1.6 million) received in July, the company increased its cash and cash equivalents to € 8.3 million, compared to € 7.9 million as of June 30th, 2019. The company’s cash burn rate has been steadily declining since the second half of 2018, down to € 0.4 million per month this quarter. The EIB (European Investment Bank) loan is expected to be finalized in Q4, 2019.

In the third quarter, the iCRO business exceeded the mark of 100 clinical studies contracted with biopharmaceutical sponsors, with a growing number of phase III studies and immuno-oncology trials (+45%). The company is experiencing an increase in repeat business with large biopharmaceutical companies, which shows a great deal of trust in Median’s performance, quality and competitiveness.

Meanwhile, Median continued to develop its imaging phenomics platform iBiopsy. A demo was successfully featured at the annual conference of the European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) (ESMO – September 27th to 30th, 2019, Barcelona, Spain), creating a lot of traction and interest by pharma groups.

"Our continued iCRO excellent performance validates the strategic decisions we made in 2018. Our iCRO business is demonstrating its capacity for sustainable growth and profitability," said Fredrik Brag, CEO and co-founder of Median. "With iBiopsy, Median is at the forefront of the development of non-invasive biomarker diagnostic solutions, which are currently generating great interest from US investors. Liquid biopsy companies have multibillion-dollar valuations. In oncology, the two obvious oncology non-invasive biomarker diagnostic solutions are liquid biopsies and imaging and we intend to become the leader in imaging", he added.

On October 8, 2019 Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, reported that the company will present at Advances in Immuno-Oncology Congress USA 2019 in San Diego on October 8th at 2:50 PM PDT (Press release, Personalis, OCT 8, 2019, View Source [SID1234540114]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation, titled "Advancing Precision Oncology Biomarker Discovery with a Multidimensional Immunogenomics Platform," will describe the Personalis universal cancer immunogenomics platform, ImmunoID NeXT. In addition to an overview, the presentation will cover preliminary data from an ongoing study in which this platform is being used to evaluate IO-related biomarkers and potential tumor escape mechanisms in a cohort of melanoma patients treated with anti-PD-1 therapy.

ImmunoID NeXT is the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. The platform can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one. This maximizes the biological information that can be generated from a precious tumor specimen.

The presentation will be delivered by Kedar Hastak, Ph.D., Field Application Scientist.

On October 8, 2019 BostonGene Corporation (BostonGene), a Boston, Mass-based biomedical software company, reported a master agreement with Washington University School of Medicine in St. Louis to collaborate on multiple research projects (Press release, BostonGene, OCT 8, 2019, View Source [SID1234540113]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BostonGene’s solution will provide Washington University oncologists at Siteman Cancer Center with detailed analysis, interpretation and visualization of big data obtained from cancer patient’s genomic, transcriptomic, proteomic and imaging tests. The solution identifies all significant somatic alterations, evaluates protein expression, computes tumor clonality, tumor heterogeneity, tumor microenvironment cell type composition, hereditary predisposition, viral infestation, pharmacogenomics and predicts neoantigens for personalized vaccine development among other molecular features. BostonGene generates a visually-appealing and self-explanatory tumor schematics, called MF PortraitTM, elegantly depicting tumor activity, tumor cellular composition, activity of immune-microenvironment and other tumor-associated processes.

"We’re collaborating with BostonGene to evaluate how its technology can help us identify the best treatments for patients based on the underlying characteristics of their cancers, with the goal of increasing survival. The company’s analytics and integration of scientific and clinical knowledge is aimed at complementing and empowering the precision medicine approach for individual cancer patients," said Todd Fehniger, MD/PhD, a Washington University medical oncologist who treats patients at Siteman Cancer Center.

"BostonGene’s mission is to provide every patient with the highest probability of survival by selecting optimal cancer treatments using sophisticated analytics and integration of scientific and clinical knowledge," said Andrew Feinberg, President and CEO of BostonGene. "With our collaboration with Washington University we are transforming cancer care from treating a diagnosis to treating the patient."